BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Hemophilia Alliance - ECPv6.3.7//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://hemoalliance.org
X-WR-CALDESC:Events for Hemophilia Alliance
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240507T140000
DTEND;TZID=America/New_York:20240507T150000
DTSTAMP:20260406T133453
CREATED:20240311T173328Z
LAST-MODIFIED:20240311T173328Z
UID:46401-1715090400-1715094000@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A webinar from Genentech - Reinforcing 10+ years of clinical trial experience with a subcutaneous prophylaxis treatment
DESCRIPTION:Date: Tuesday\, May 7\, 2024\nTime: 2:00pm – 3:00pm ET \n\n \nTITLE:\nReinforcing 10+ years of clinical trial experience with a subcutaneous prophylaxis treatment\, including the latest data in infants \nWEBINAR OBJECTIVE:\nDr. Mike Silvey will share his perspective on managing patients with hemophilia A using a subcutaneous prophylactic treatment. The presentation will include the pivotal efficacy and safety data that is the foundation of the ongoing clinical trial program in patients with and without FVIII inhibitors\, including an overview of real-world experience. Dr. Silvey will share updates from the latest trial in infants and previously untreated patients. The webinar will feature brain teasers\, and showcase social media that’s engaging the hemophilia community and polls. Q&A session will follow the program.  \nSPEAKER:\n\nMichael Silvey\, DO\nHTC Director – Children’s Mercy HTC\, Kansas City\, MO.\nAssociate Professor of Pediatrics – University of Missouri-Kansas City School of Medicine. \nSPEAKER’S BIO:\nMichael Silvey\, DO\, is an Associate Professor of Pediatrics at the University of Missouri-Kansas City School of Medicine and the Associate Director of the Kansas City Regional Hemophilia Treatment Center at Children’s Mercy Hospital in Kansas City\, Missouri. He received his medical degree from The Chicago College of Osteopathic Medicine. He completed his general pediatrics residency at the University of Texas Health Science Center-San Antonio and his pediatric hematology/oncology fellowship at Children’s Mercy Hospital in Kansas City\, Missouri. His primary clinical and research interests are hemophilia\, inherited platelet function disorders\, and the coagulation system in patients with congenital heart disease as well as patients need ECMO. Dr. Silvey serves as a primary investigator for several research studies involving both bleeding and clotting disorders. In addition to enjoying taking care of pediatric bleeding disorder patients\, he also likes to spend lots of time with his wife and two children and getting out on the golf course.
URL:https://hemoalliance.org/alliance-events/a-webinar-from-genentech-reinforcing-10-years-of-clinical-trial-experience-with-a-subcutaneous-prophylaxis-treatment/
CATEGORIES:Members Only,Webinar
END:VEVENT
END:VCALENDAR